WO2002078682A3 - Estrogen replacement therapy - Google Patents

Estrogen replacement therapy Download PDF

Info

Publication number
WO2002078682A3
WO2002078682A3 PCT/US2002/007971 US0207971W WO02078682A3 WO 2002078682 A3 WO2002078682 A3 WO 2002078682A3 US 0207971 W US0207971 W US 0207971W WO 02078682 A3 WO02078682 A3 WO 02078682A3
Authority
WO
WIPO (PCT)
Prior art keywords
replacement therapy
estrogen replacement
perimenopausal
menopausal
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/007971
Other languages
French (fr)
Other versions
WO2002078682A2 (en
Inventor
James Harrison Pickar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23057754&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002078682(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to IL15794302A priority Critical patent/IL157943A0/en
Priority to CA002441252A priority patent/CA2441252A1/en
Priority to EA200301023A priority patent/EA200301023A1/en
Priority to PL02364675A priority patent/PL364675A1/en
Priority to EP02757788A priority patent/EP1368037A2/en
Priority to BR0208165-2A priority patent/BR0208165A/en
Priority to AU2002338277A priority patent/AU2002338277B2/en
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to MXPA03008366A priority patent/MXPA03008366A/en
Priority to JP2002576948A priority patent/JP2004524354A/en
Priority to HU0500346A priority patent/HUP0500346A2/en
Priority to KR10-2003-7012066A priority patent/KR20030090673A/en
Publication of WO2002078682A2 publication Critical patent/WO2002078682A2/en
Priority to NO20034098A priority patent/NO20034098L/en
Anticipated expiration legal-status Critical
Publication of WO2002078682A3 publication Critical patent/WO2002078682A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)

Abstract

This invention relates to methods and pharmaceutical compositions for providing estrogen replacement therapy in perimenopausal, menopausal, and postmenopausal women through the continuous administration of conjugated estrogens.
PCT/US2002/007971 2001-03-16 2002-03-15 Estrogen replacement therapy Ceased WO2002078682A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
KR10-2003-7012066A KR20030090673A (en) 2001-03-16 2002-03-15 Estrogen Replacement Therapy
MXPA03008366A MXPA03008366A (en) 2001-03-16 2002-03-15 Estrogen replacement therapy.
EA200301023A EA200301023A1 (en) 2001-03-16 2002-03-15 REPLACEMENT THERAPY WITH ESTROGENS
PL02364675A PL364675A1 (en) 2001-03-16 2002-03-15 Estrogen replacement therapy
EP02757788A EP1368037A2 (en) 2001-03-16 2002-03-15 Estrogen replacement therapy
BR0208165-2A BR0208165A (en) 2001-03-16 2002-03-15 Pharmaceutical compositions and their uses in estrogen replacement therapy
AU2002338277A AU2002338277B2 (en) 2001-03-16 2002-03-15 Estrogen replacement therapy
IL15794302A IL157943A0 (en) 2001-03-16 2002-03-15 Estrogen replacement therapy
HU0500346A HUP0500346A2 (en) 2001-03-16 2002-03-15 Use of conjugated estrogens in estrogen replacement therapy to produce effective pharmaceutical preparations
CA002441252A CA2441252A1 (en) 2001-03-16 2002-03-15 Estrogen replacement therapy
JP2002576948A JP2004524354A (en) 2001-03-16 2002-03-15 Estrogen replacement therapy
NO20034098A NO20034098L (en) 2001-03-16 2003-09-15 Östrogenerstatningsterapi

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27670401P 2001-03-16 2001-03-16
US60/276,704 2001-03-16

Publications (2)

Publication Number Publication Date
WO2002078682A2 WO2002078682A2 (en) 2002-10-10
WO2002078682A3 true WO2002078682A3 (en) 2003-10-09

Family

ID=23057754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/007971 Ceased WO2002078682A2 (en) 2001-03-16 2002-03-15 Estrogen replacement therapy

Country Status (18)

Country Link
US (2) US20020173499A1 (en)
EP (1) EP1368037A2 (en)
JP (1) JP2004524354A (en)
KR (1) KR20030090673A (en)
CN (2) CN1633299A (en)
AR (1) AR035946A1 (en)
AU (1) AU2002338277B2 (en)
BR (1) BR0208165A (en)
CA (1) CA2441252A1 (en)
EA (1) EA200301023A1 (en)
HU (1) HUP0500346A2 (en)
IL (1) IL157943A0 (en)
MX (1) MXPA03008366A (en)
NO (1) NO20034098L (en)
PL (1) PL364675A1 (en)
SG (1) SG154323A1 (en)
WO (1) WO2002078682A2 (en)
ZA (1) ZA200308029B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1857110A3 (en) * 2001-03-16 2008-08-06 Wyeth Hormone replacement therapy
MXPA03008367A (en) * 2001-03-16 2004-11-12 Wyeth Corp Hormone replacement therapy.
JP5143993B2 (en) * 2003-03-26 2013-02-13 株式会社産学連携機構九州 Estrogen-like active agent
MXPA05010871A (en) * 2003-04-11 2005-11-25 Barr Lab Inc Methods of administering estrogens and progestins.
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
EP1781628A2 (en) * 2004-08-26 2007-05-09 Wyeth a Corporation of the State of Delaware Prodrug substituted benzoxazoles as estrogenic agents
WO2007076144A2 (en) * 2005-12-27 2007-07-05 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
WO2007085020A2 (en) * 2006-01-20 2007-07-26 Pear Tree Pharmaceuticals, Inc. Method of treating atrophic vaginitis
MX2008012880A (en) * 2006-04-05 2008-10-13 Wyeth Corp Methods for prevention and treatment of conditions arising from local estrogen deficiency.
US20070254036A1 (en) * 2006-04-13 2007-11-01 Besins Healthcare Sa Treatment of menopause associated symptoms
BRPI0711525A2 (en) * 2006-06-02 2011-11-01 Pear Tree Women S Health Care Pharmaceutical composition and method for treating symptoms of atrophic vaginitis
EP2044943A1 (en) * 2007-10-04 2009-04-08 Solvay Pharmaceuticals, Inc. Pharmaceutical compositions comprising esterified estrogens and methyltestosterone and method of using the same
CA2704921C (en) * 2007-11-06 2015-11-24 Ellis L. Kline Compositions and methods for treating parkinson's disease and related disorders
JP2012502988A (en) * 2008-09-16 2012-02-02 プレイテックス プロダクツ エルエルシー Preparations for menstrual suppression, contraception and hormone replacement therapy, and methods of administration thereof
KR101665261B1 (en) 2015-08-06 2016-10-12 순천향대학교 산학협력단 Compositions for treating or detecting atrophic vaginitis
CN114573654B (en) * 2020-12-01 2025-09-12 北京奇明达企业管理有限公司 Self-assembled trimers of 17-O-acetyl-17-β estradiol, their preparation, activity and applications

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608075A (en) * 1969-07-28 1971-09-21 American Home Prod Compositions and methods of treating the menopausal syndrome
US3639599A (en) * 1967-10-19 1972-02-01 Merck Patent Gmbh Uterotropic composition
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
EP0322020A1 (en) * 1987-12-22 1989-06-28 Akzo N.V. Pharmaceutical dosage unit for treating climacteric complaints and osteoporosis
US4980358A (en) * 1988-04-04 1990-12-25 George D. McAdory Method employing gonadal hormones and dopamine agonist intended for combined use in the improvement of lymphocyte function
WO1992013538A1 (en) * 1991-02-01 1992-08-20 Chiesi Farmaceutici S.P.A. Pharmaceutical combination for the prevention and treatment of postmenopausal osteoporosis
WO1994009789A1 (en) * 1992-11-02 1994-05-11 American Home Products Corporation USE OF 17α-DIHYDROEQUILENIN FOR LOWERING CHOLESTEROL
WO1994022457A1 (en) * 1993-04-02 1994-10-13 The Regents Of The University Of California Method and composition for treatment of osteoporosis
DE4326948C1 (en) * 1993-08-11 1994-11-17 Klaus Dr Med Umbreit Use of natural oestrogens for slowing down the aging process in men
EP0722720A1 (en) * 1995-01-17 1996-07-24 American Home Products Corporation Novel sugar coating composition for application to compressed medicinal tablets
WO1998016544A1 (en) * 1996-10-11 1998-04-23 American Home Products Corporation 8(9)-dehydroestradiol derivatives
WO1998045315A1 (en) * 1997-04-07 1998-10-15 American Home Products Corporation Estra-5(10),7-dienes with estrogenic activity
WO1998050414A1 (en) * 1997-05-05 1998-11-12 American Home Products Corporation B-ring estratriene diol sulphates
WO1998050413A1 (en) * 1997-05-02 1998-11-12 American Home Products Corporation Pharmaceutically acceptable salts of 3-hydroxy-estr-5(10)-en-17-one 3-sulphate active as estrogens
WO1999012531A2 (en) * 1997-09-11 1999-03-18 Hesch Rolf Dieter Hormonal contraceptive
WO1999059969A1 (en) * 1998-05-15 1999-11-25 American Home Products Corporation Compositions comprising 2-phenyl-indole compounds and estrogen formulations
WO2001000215A1 (en) * 1999-06-25 2001-01-04 Wake Forest University Compositions for treating or preventing neurodegeneration and cognitive decline
WO2001035106A2 (en) * 1999-11-05 2001-05-17 Wyeth Methods for identifying and using amyloid-inhibitory compounds
WO2002058706A2 (en) * 2000-12-22 2002-08-01 Endeavor Pharmaceuticals Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
WO2002074292A2 (en) * 2001-03-16 2002-09-26 Wyeth Hormone replacement therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639599A (en) * 1967-10-19 1972-02-01 Merck Patent Gmbh Uterotropic composition
US3608075A (en) * 1969-07-28 1971-09-21 American Home Prod Compositions and methods of treating the menopausal syndrome
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
EP0322020A1 (en) * 1987-12-22 1989-06-28 Akzo N.V. Pharmaceutical dosage unit for treating climacteric complaints and osteoporosis
US4980358A (en) * 1988-04-04 1990-12-25 George D. McAdory Method employing gonadal hormones and dopamine agonist intended for combined use in the improvement of lymphocyte function
WO1992013538A1 (en) * 1991-02-01 1992-08-20 Chiesi Farmaceutici S.P.A. Pharmaceutical combination for the prevention and treatment of postmenopausal osteoporosis
WO1994009789A1 (en) * 1992-11-02 1994-05-11 American Home Products Corporation USE OF 17α-DIHYDROEQUILENIN FOR LOWERING CHOLESTEROL
WO1994022457A1 (en) * 1993-04-02 1994-10-13 The Regents Of The University Of California Method and composition for treatment of osteoporosis
DE4326948C1 (en) * 1993-08-11 1994-11-17 Klaus Dr Med Umbreit Use of natural oestrogens for slowing down the aging process in men
EP0722720A1 (en) * 1995-01-17 1996-07-24 American Home Products Corporation Novel sugar coating composition for application to compressed medicinal tablets
WO1998016544A1 (en) * 1996-10-11 1998-04-23 American Home Products Corporation 8(9)-dehydroestradiol derivatives
WO1998045315A1 (en) * 1997-04-07 1998-10-15 American Home Products Corporation Estra-5(10),7-dienes with estrogenic activity
WO1998050413A1 (en) * 1997-05-02 1998-11-12 American Home Products Corporation Pharmaceutically acceptable salts of 3-hydroxy-estr-5(10)-en-17-one 3-sulphate active as estrogens
WO1998050414A1 (en) * 1997-05-05 1998-11-12 American Home Products Corporation B-ring estratriene diol sulphates
WO1999012531A2 (en) * 1997-09-11 1999-03-18 Hesch Rolf Dieter Hormonal contraceptive
WO1999059969A1 (en) * 1998-05-15 1999-11-25 American Home Products Corporation Compositions comprising 2-phenyl-indole compounds and estrogen formulations
WO2001000215A1 (en) * 1999-06-25 2001-01-04 Wake Forest University Compositions for treating or preventing neurodegeneration and cognitive decline
WO2001035106A2 (en) * 1999-11-05 2001-05-17 Wyeth Methods for identifying and using amyloid-inhibitory compounds
WO2002058706A2 (en) * 2000-12-22 2002-08-01 Endeavor Pharmaceuticals Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
WO2002074292A2 (en) * 2001-03-16 2002-09-26 Wyeth Hormone replacement therapy

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ARCHER D F ET AL: "Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate.", OBSTETRICS & GYNECOLOGY, vol. 83, no. 5, 1994, pages 686 - 692, XP008018152, ISSN: 0029-7844 *
BEERS, M. AND BERKOW R.: "The Merck Manual of Diagnosis and Therapy - Seventeenth Edition", MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION, N.J., XP002226922 *
CHEANG A ET AL: "A risk-benefit appraisal of transdermal estradiol therapy.", DRUG SAFETY: AN INTERNATIONAL JOURNAL OF MEDICAL TOXICOLOGY AND DRUG EXPERIENCE. NEW ZEALAND NOV 1993, vol. 9, no. 5, November 1993 (1993-11-01), pages 365 - 379, XP008018150, ISSN: 0114-5916 *
ETTINGER B.: "Personal perspective on low-dose estrogen therpay for postmenopausal women.", MENOPAUSE, vol. 6, 1999, pages 273 - 276, XP008018271 *
GEOLA F L ET AL: "BIOLOGICAL EFFECTS OF VARIOUS DOSES OF CONJUGATED EQUINE ESTROGENS IN POST MENOPAUSAL WOMEN", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 51, no. 3, 1980, pages 620 - 625, XP001131919, ISSN: 0021-972X *
MAGOS A L ET AL: "AMENORRHEA AND ENDOMETRIAL ATROPHY WITH CONTINUOUS ORAL ESTROGEN AND PROGESTOGEN THERAPY IN POSTMENOPAUSAL WOMEN", OBSTETRICS AND GYNECOLOGY, vol. 65, no. 4, 1985, pages 496 - 499, XP008018151, ISSN: 0029-7844 *
MCNICHOLAS M.M.J. ET AL: "Pain and increased mammographic density in women receiving hormone replacement therapy: A prospective study.", AMERICAN JOURNAL OF ROENTGENOLOGY, (1994) 163/2 (311-315)., XP008018224 *
PARFITT K.: "Martindale - The complete drug reference - Thirthy-second edition", PHARMACEUTIACL PRESS, LONDON UK, XP002226921 *
ROMER W ET AL: "Novel @?scavestrogens@? and their radical scavenging effects, iron-chelating, and total antioxidative activities: DELTA-dehydro derivatives of 17alpha-estradiol and 17beta-estradiol", STEROIDS: STRUCTURE, FUNCTION, AND REGULATION, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, vol. 62, no. 3, 1 March 1997 (1997-03-01), pages 304 - 310, XP004057109, ISSN: 0039-128X *

Also Published As

Publication number Publication date
KR20030090673A (en) 2003-11-28
EA200301023A1 (en) 2004-02-26
BR0208165A (en) 2004-03-30
ZA200308029B (en) 2010-04-28
AR035946A1 (en) 2004-07-28
PL364675A1 (en) 2004-12-13
NO20034098L (en) 2003-11-13
SG154323A1 (en) 2009-08-28
CN1633299A (en) 2005-06-29
AU2002338277B2 (en) 2007-11-22
US20060142258A1 (en) 2006-06-29
EP1368037A2 (en) 2003-12-10
CA2441252A1 (en) 2002-10-10
JP2004524354A (en) 2004-08-12
IL157943A0 (en) 2004-03-28
CN1879629A (en) 2006-12-20
HUP0500346A2 (en) 2005-07-28
NO20034098D0 (en) 2003-09-15
US20020173499A1 (en) 2002-11-21
WO2002078682A2 (en) 2002-10-10
MXPA03008366A (en) 2004-11-12

Similar Documents

Publication Publication Date Title
WO2001070208A3 (en) Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate
WO2002074292A3 (en) Hormone replacement therapy
WO2002078682A3 (en) Estrogen replacement therapy
MXPA02012891A (en) Pharmaceutical compositions of estrogenic agents.
IL154888A0 (en) Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid
WO2004043363A8 (en) Protein-stabilized liposomal formulations of pharmaceutical agents
AU5181200A (en) Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
WO2002070438A3 (en) Compositions for delivering bisphosphonates
ZA200007299B (en) Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol.
HUP0401935A3 (en) Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof
EP1632237A3 (en) Compositions comprising drospirenone and a complex between ethinyl-estradiol and a cyclodextrin
WO2000007979A3 (en) Compounds and compositions for delivering active agents
ZA200308809B (en) Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins.
MXPA03007857A (en) Compounds and compositions for delivering active agents.
HRP20090418T1 (en) PHARMACEUTICAL PREPARATION CONTAINING GESTAGENS AND / OR ESTROGENS AND 5-METHYL- (6S) -TETRAHYDROFOLATE
WO2002015959A3 (en) Compounds and compositions for delivering active agents
WO2006023496A3 (en) Vaginal cream compositions, kits thereof and methods of using thereof
BG102660A (en) Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders
TNSN03043A1 (en) 2h-1 benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
AU2001258443A1 (en) Drug delivery device, especially for the delivery of gestodene
WO2003084521A3 (en) Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
AU2001258442A1 (en) Drug delivery device, especially for the delivery of levonorgestrel
WO2002074315A8 (en) Pharmaceutical combined preparations containing aromatase inhibitors and substances having an estrogen effect in addition to the use thereof for producing a medicament for estrogen-replacement-therapy
BR0308968A (en) hormone replacement therapy
EP1857110A3 (en) Hormone replacement therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1-2003-500895

Country of ref document: PH

Ref document number: 2441252

Country of ref document: CA

Ref document number: PA/a/2003/008366

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002757788

Country of ref document: EP

Ref document number: 2002338277

Country of ref document: AU

Ref document number: 2002576948

Country of ref document: JP

Ref document number: 157943

Country of ref document: IL

Ref document number: 1020037012066

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 528375

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200308029

Country of ref document: ZA

Ref document number: 200301023

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 028101162

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002757788

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 2002757788

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002757788

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2002338277

Country of ref document: AU

Date of ref document: 20020315

Kind code of ref document: B